Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.1342
- Book/Share 32.4693
- PB 4.6422
- Debt/Equity 0.669
- CurrentRatio 1.2574
- ROIC 0.1201
- MktCap 362666931100.0
- FreeCF/Share 7.7211
- PFCF 19.5255
- PE 16.6254
- Debt/Assets 0.2698
- DivYield 0.0333
- ROE 0.2995
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Smart Moves With $5,000: Dividend Stocks to Own Amid Market Chaos
Published: June 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Allocating 10% to 20% to dividend stocks balances growth-heavy portfolios, leveraging compounding returns to navigate geopolitical and monetary challenges.
Read More
Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”
Published: June 17, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big pharma provides the infrastructure and market access.
Read More
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
Read More
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose MILAN , June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell …
Read More
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Published: June 12, 2025 by: PRNewsWire
Sentiment: Neutral
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation MILAN , June 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The …
Read More
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Read More
3 Top Dividend Stocks Analysts Are Bullish on Right Now
Published: June 06, 2025 by: MarketBeat
Sentiment: Positive
We're at the end of earnings season. That means it's time for analysts to weigh in on the outlook for specific stocks.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
Read More
3 Fortress Dividend Stocks Set to Thrive, Even if the Economy Slumps
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend stocks have solid underlying businesses. The cash flows should remain consistent regardless of the broader economic environment.
Read More
Top 3 dividend stocks to buy for 2026
Published: June 04, 2025 by: Finbold
Sentiment: Positive
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.
Read More
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These …
Read More
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent.
Read More
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO ® in transplant-ineligible newly diagnosed patients CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly …
Read More
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1
Read More
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA.
Read More
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
Published: June 02, 2025 by: Schwab Network
Sentiment: Positive
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Read More
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company's structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major drugs like Darzalex Faspro.
Read More
Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Bernstein's 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right, thank you, everybody. Thanks, guys.
Read More
No Rolex For Me - I'm Buying Dividends That Pay For Life
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable long-term returns. A $10K McDonald's investment in 2004 would've yielded over $22K in dividends alone. History shows that strong-yielding dividend stocks, especially those in the second quintile, have consistently outperformed the market with lower risk.
Read More
FDA Panel Reiterates the Cancer Risks of Talc
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
WASHINGTON--(BUSINESS WIRE)--A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals. Many of the experts cited the more than 30 years of studies showing an association between talc use and ovarian cancer, which led Johnson & Johnson (NYSE:JNJ) to remove the company's iconic body powders from the market in recent years. “It's.
Read More
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.
Read More
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Negative
J&J's JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others.
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma RARITAN, N.J. , May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM).
Read More
Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh Hello everyone, I am Shagun Singh, Senior Research Analyst at RBC, and I'm very happy to host the next session with Johnson & Johnson. Joining us from the company is Joe Wolk, Chief Financial Officer of the company.
Read More
Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts
Published: May 20, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024. Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen. The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed wi.
Read More
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple and Johnson & Johnson hold Moody's highest credit rating of Aaa, reflecting exceptional financial strength and stability. Alphabet and Berkshire Hathaway are rated Aa2 by Moody's, indicating very high credit quality, just below the top tier.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Mr. Joaquin Duato
- Employees 138100